Drug Approval | May 27, 2023
Eugia Pharma receives USFDA approval for Carboprost Tromethamine Injection
The product is expected to be launched in June 2023
The product is expected to be launched in June 2023
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
The Velcade Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Silo enters into commercial evaluation license agreement for next generation liposomes
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Subscribe To Our Newsletter & Stay Updated
